Table of Content

1. Executive Summary


2. Global Chimeric Antigen Receptor (CAR)-T cell Therapy Market


3. Market Share – CAR-T Cell Therapy

3.1 By Geographical Region
3.2 By Targeted Antigens


4. Targeted Antigen Market

4.1 CD19

4.1.1 Introduction
4.1.2 Market Size and Forecast

4.2 CD20

4.2.1 Introduction
4.2.2 Market Size and Forecast

4.3 GD2

4.3.1 Introduction
4.3.2 Market Size and Forecast

4.4 CD22

4.4.1 Introduction
4.4.2 Market Size and Forecast

4.5 CD30

4.5.1 Introduction
4.5.2 Market Size and Forecast

4.6 CD33

4.6.1 Introduction
4.6.2 Market Size and Forecast

4.7 HER2

4.7.1 Introduction
4.7.2 Market Size and Forecast

4.8 Mesothelin (MESO)

4.8.1 Introduction
4.8.2 Market Size and Forecast

4.9 EGFRvIII

4.9.1 Introduction
4.9.2 Market Size and Forecast

4.10 Others

4.10.1 Market Size and Forecast


5. Geographical CAR-T Cell Therapy Market (2016 -2026)

5.1 North America
5.2 Europe
5.3 Asia Pacific
5.4 Latin America
5.5 Middle East
5.6 Africa


6. Global - CAR-T Cell Clinical Trials/Study

6.1 CD19
6.2 CD20
6.3 CD22
6.4 CD30
6.5 CD33
6.6 EGFRvIII
6.7 GD2
6.8 HER1
6.9 HER2
6.10 MESO


7. China CAR-T Cells Clinical Trials Details

7.1 By Cities CAR-T Cells Clinical Trials
7.2 CD19 Directed CAR-T Cells Clinical Trials
7.3 Non-CD19 Directed CAR-T Cells Clinical Trials
7.4 Solid Tumors CAR-T Cells Clinical Trials


8. CAR-T Cell Therapy SWOT Analysis

8.1 Strength
8.2 Weakness
8.3 Opportunities
8.4 Threats


9. Regulation in CAR-T Cell Therapy

9.1 United States
9.2 European Union
9.3 China


10. IPO/Investment/Funding/Partnership in CAR-T Cell Therapy Market

10.1 Venture Capital Investment
10.2 Initial Public Offerings of CAR-T Companies
10.3 CAR-T Companies Strategic Partnerships/Deals
10.4 Key CAR-T Technology Deals


11. Growth Drivers

11.1 FDA Approvals of CAR-T Therapy
11.2 Dramatically Increasing Number of CAR-T Cell Trials Globally


12. Challenges

12.1 Regulatory Challenges
12.2 Very Expensive CAR-T Therapy Treatment


13. Novartis

13.1 Company Overview
13.2 Initiatives

13.2.1 Point 1
13.2.2 Point 2 Kymriah? (tisagenlecleucel), First-in-class CAR-T Therapy from Novartis Received Second FDA Approval
13.2.3 Point 2

13.3 Financial Insight


14. Gilead Sciences (Kite Pharma)

14.1 Company Overview
14.2 Company Initiatives

14.2.1 Point 1
14.2.2 Point 2

14.3 Company Financial Insight


15. Celgene Corporation (Juno Therapeutics)

15.1 Company Overview
15.2 Company Initiatives

15.2.1 Point 1
15.2.2 Point 2

15.3 Company Financial Insight


16. Celyad

16.1 Company Overview
16.2 Company Initiatives

16.2.1 Point 1
16.2.2 Point 2
16.2.3 Point 3

16.3 Financial Insight



List of Figures



Figure 2_1: Global – CAR-T Cell Therapy Market (Million US$), 2017 – 2019
Figure 2_2: Global – Forecast for CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 3_1: Global – CAR-T Cell Therapy Regional Market Share (Percent), 2017 – 2019
Figure 3_2: Global – Forecast for CAR-T Cell Therapy Regional Market Share (Percent), 2020 – 2028
Figure 4_1: Global – CD19 Antigen CAR-T Cell Therapy Market (Million US$), 2017 – 2019
Figure 4_2: Global – CD19 Antigen CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 4_3: Global – Forecast for CD20 Antigen CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 4_4: Global – Forecast for GD2 Antigen CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 4_5: Global – Forecast for CD22 Antigen CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 4_6: Global – Forecast for CD30 Antigen CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 4_7: Global – Forecast for CD33 Antigen CAR-T Cell Therapy Market (Million US$), 2017 – 2028
Figure 4_8: Global – Forecast for HER2 Antigen CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 4_9: Global – Forecast for MESO Antigen CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 4_10: Global – Forecast for EGFRvIII Antigen CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 4_11: Global – Forecast for Others Antigen CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 5_1: North America – CAR-T Cell Therapy Market (Million US$), 2017 – 2019
Figure 5_2: North America – Forecast for CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 5_3: Europe – CAR-T Cell Therapy Market (Million US$), 2017 – 2019
Figure 5_4: Europe – Forecast for CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 5_5: Asia Pacific – CAR-T Cell Therapy Market (Million US$), 2017 – 2019
Figure 5_6: Asia Pacific – Forecast for CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 5_7: Latin America – CAR-T Cell Therapy Market (Million US$), 2017 – 2019
Figure 5_8: Latin America – Forecast for CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 5_9: Middle East – CAR-T Cell Therapy Market (Million US$), 2017 – 2019
Figure 5_10: Middle East – Forecast for CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 5_11: Africa – CAR-T Cell Therapy Market (Million US$), 2017 – 2019
Figure 5_12: Africa – Forecast for CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 7_1: China – By Cities CAR-T Cells Clinical Trials (Number), 2017
Figure 11_1: Global – CAR-T New & Total Clinical Trials (Number), 2012-2017
Figure 11_2: Global – By Phase CAR-T Clinical Trials (Number), 2017
Figure 13_1: Novartis – Global Sales (Million US$), 2015 - 2019
Figure 13_2: Novartis – Forecast for Global Sales (Million US$), 2020 - 2028
Figure 14_1: Gilead Sciences – Global Sales (Million US$), 2017 - 2019
Figure 14_2: Gilead Sciences – Forecast for Global Sales (Million US$), 2020 - 2028
Figure 15_1: Celgene – Global Sales (Million US$), 2013 - 2019
Figure 15_2: Celgene – Forecast for Global Sales (Million US$), 2020 - 2028
Figure 16_1: Celyad – Global Sales (Million US$), 2013 - 2019
Figure 16_2: Celyad – Forecast for Global Sales (Million US$), 2020 - 2028


List of Tables


Table 3 1: Global – Current & Forecast for CAR-T Cell Therapy Targeted Antigens Market Share (Percent), 2017 – 2028
Table 6 1: Global – Details of CD19 CAR-T Studies, 2018
Table 6 2: Global – Details of CD20 CAR-T Studies, 2018
Table 6 3: Global – Details of CD22 CAR-T Studies, 2018
Table 6 4: Global – Details of CD30 CAR-T Studies, 2018
Table 6 5: Global – Details of CD33 CAR-T Studies, 2018
Table 6 6: Global – Details of EGFRvIII CAR-T Studies, 2018
Table 6 7: Global – Details of GD2 CAR-T Studies, 2018
Table 6 8: Global – Details of HER1 CAR-T Studies, 2018
Table 6 9: Global – Details of HER2 CAR-T Studies, 2018
Table 6 10: Global – Details of MESO CAR-T Studies, 2018
Table 7 1: China - CD19 Directed CAR-T Cells Clinical Trials, 2017
Table 7 2: China – Non-CD19 Directed CAR-T Cells Clinical Trials, 2017
Table 7 3: China – Solid Tumors CAR-T Cells Clinical Trials, 2017
Table 10 1: Global – Venture Capital Investments (Million US$) in CAR-T Cell Therapy, 2011 – 2017
Table 10 2: Global – Initial Public Offerings (Million US$) in CAR-T Cell Therapy, 2011 – 2016
Table 10 3: Global - CAR-T Companies Strategic Partnerships/Acquisitions, 2012-2017
Table 10 4: Global – Key CAR-T Technology Deals, 2012-2017